Phio Pharmaceuticals is a biotechnology company developing immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. Co. is focused on its proprietary INTASYL platform with utility in immune cells and/or the tumor micro-environment. Co. has two product candidates that are being developed for use in Adoptive Cell Transfer, PH-762 and PH-804. Co.'s primary pipeline compound, PH-762, targets the checkpoint protein PD-1, a checkpoint protein on immune cells. Co.'s second pipeline compound, PH-804, targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells. The PHIO stock yearly return is shown above.
The yearly return on the PHIO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PHIO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|